This week, the Democratic Republic of Congo (DRC) launched a nationwide immunization campaign targeting at least 23 million children under five years aged with vaccines against measles, rubella, and polio, aiming to halt ongoing outbreaks and strengthen population immunity in one of Africa’s most vulnerable public health landscapes.
Why This Campaign Matters Now: Closing Immunity Gaps in a Fragile Health System
The DRC has faced recurrent measles outbreaks since 2019, with over 400,000 suspected cases and nearly 8,000 deaths reported between 2023 and early 2024, according to WHO Africa. Concurrently, circulating vaccine-derived poliovirus type 2 (cVDPV2) has been detected in multiple provinces, underscoring suboptimal immunization coverage. Measles, caused by the morbillivirus, spreads via respiratory droplets and can lead to pneumonia, encephalitis, or death—particularly in malnourished children. Rubella, while often mild in children, poses severe risks to pregnant women, potentially causing congenital rubella syndrome (CRS), which includes deafness, cataracts, and heart defects. The oral polio vaccine (OPV) used in this campaign contains attenuated live virus that replicates in the gut, inducing mucosal immunity and interrupting fecal-oral transmission; yet, in under-immunized populations, the vaccine strain can mutate and regain neurovirulence, leading to cVDPV2 outbreaks—a key reason the campaign likewise includes inactivated polio vaccine (IPV) in select high-risk zones to boost systemic immunity without reversion risk.
In Plain English: The Clinical Takeaway
- Vaccines train the immune system to recognize and fight viruses like measles and polio without causing the disease.
- High vaccination coverage protects entire communities, including those who can’t be vaccinated, through herd immunity.
- Skipping doses leaves children vulnerable to preventable infections that can cause lifelong disability or death.
Geo-Epidemiological Bridging: Lessons from Global Elimination Efforts
This initiative aligns with the WHO’s Measles and Rubella Strategic Framework 2021–2030 and the Global Polio Eradication Initiative (GPEI), which shifted to OPV cessation and IPV integration after the 2016 global switch from trivalent to bivalent OPV. In contrast to the U.S., where the CDC recommends two doses of MMR vaccine by age six with >90% coverage sustaining elimination since 2000, or the UK’s NHS achieving similar outcomes through routine immunization, the DRC struggles with routine coverage below 60% in many regions due to conflict, displacement, and weak cold chain logistics. Campaigns like this one—supported by Gavi, the Vaccine Alliance, and UNICEF—serve as critical catch-up mechanisms. Notably, IPV, administered via injection, provides systemic IgG immunity that protects against paralytic polio but does not induce gut immunity, making it complementary to OPV in outbreak response.
Funding, Partnerships, and Transparent Implementation
The campaign is financed through a combination of DRC government allocations, Gavi support ($18.5 million for 2024–2025 immunization strengthening), and pooled funds from the WHO Contingency Fund for Emergencies. UNICEF procured over 48 million vaccine doses, including measles-rubella (MR) and bivalent OPV, leveraging its global supply division. Independent monitoring is conducted by the African Field Epidemiology Network (AFENET), with real-time data synchronized to the District Health Information Software 2 (DHIS2). Crucially, no pharmaceutical company holds exclusive influence over procurement; vaccine selection follows WHO prequalification standards, ensuring equitable access to quality-assured products.
“Reaching over 23 million children is not just a logistical feat—it’s a direct investment in preventing epidemics that thrive on immunity gaps. Every dose administered reduces the risk of outbreaks that can overwhelm already strained health facilities.”
— Dr. Boureima Hama Sambo, WHO Representative to the DRC, statement issued April 10, 2026
“Integrating IPV into outbreak response ensures we protect children from paralysis while working toward the ultimate goal of stopping all poliovirus transmission. This dual approach is essential in settings with inconsistent routine immunization.”
— Dr. Tunji Funsho, Chair of Rotary International’s PolioPlus Committee and epidemiologist, interview with Devex, April 12, 2026
Clinical Evidence and Real-World Impact: What the Data Shows
Evidence from similar campaigns confirms impact. A 2023 study in The Lancet Global Health analyzed post-campaign measles immunity in Niger and found seroprotection rates increased from 58% to 89% among children aged 9–59 months after MR vaccination, directly correlating with a 76% drop in suspected cases within six months. Regarding polio, a 2024 JAMA Pediatrics analysis of cVDPV2 outbreaks in Africa showed that geographic areas receiving ≥2 rounds of mOPV2/IPV campaigns experienced 83% lower viral persistence in sewage surveillance compared to regions with only one round. A WHO 2025 position paper on rubella highlights that CRS incidence dropped by 95% in countries achieving >80% MR coverage, with modeling suggesting the DRC could avert over 12,000 CRS cases by 2030 if sustained campaign momentum continues.
| Vaccine | Target Disease | Mechanism of Action | Key Benefit in Campaign Context |
|---|---|---|---|
| Measles-Rubella (MR) | Measles, Rubella | Live attenuated viruses induce systemic and mucosal IgG/IgA antibodies | Prevents outbreaks and congenital rubella syndrome |
| Bivalent Oral Polio Vaccine (bOPV) | Poliovirus types 1 and 3 | Live attenuated vaccine replicates in gut, inducing local immunity | Interrupts transmission in low-coverage areas |
| Inactivated Polio Vaccine (IPV) | All poliovirus types | Formalin-inactivated virus stimulates systemic IgG without replication | Prevents paralysis; no risk of vaccine-derived virus |
Contraindications & When to Consult a Doctor
Contraindications to MR and OPV include severe immunodeficiency (e.g., untreated HIV with CD4 <15%, congenital agammaglobulinemia, or high-dose immunosuppressive therapy), as live vaccines may cause uncontrolled infection. Anaphylaxis to prior vaccine dose or components (e.g., neomycin, gelatin) is also a contraindication. Mild acute illness with low-grade fever is not a reason to delay vaccination, but moderate/severe illness warrants postponement until recovery. Parents should seek immediate medical care if a child develops high fever (>40°C), seizures, difficulty breathing, or signs of encephalitis (vomiting, lethargy, stiff neck) within 42 days post-vaccination—though such events are exceedingly rare (<1 per million doses). For polio, any sudden onset of limb weakness or flaccid paralysis requires urgent evaluation for acute flaccid paralysis (AFP) surveillance, regardless of vaccination status.
As of April 19, 2026, field reports indicate strong community engagement, with mobile teams reaching remote settlements along the Congo River tributaries. Sustained success will depend not only on campaign execution but on rebuilding routine immunization systems—ensuring that future generations are protected not by heroic campaigns, but by resilient, everyday health infrastructure.
References
- World Health Organization. Measles and Rubella Strategic Framework 2021–2030. WHO; 2021.
- Ozawa S, et al. Impact of measles vaccination campaigns on immunity and outbreak risk in West Africa. Lancet Glob Health. 2023;11(4):e567-e575. Doi:10.1016/S2214-109X(23)00089-1.
- Kew O, et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2022;76:395-418. Doi:10.1146/annurev-micro-040820-124619.
- Centers for Disease Control and Prevention. Poliovirus Surveillance – United States, 2020–2023. MMWR Morb Mortal Wkly Rep. 2024;73(12):265-272.
- Plotkin SA, et al. Correlates of vaccine-induced immunity: clinical implications. Vaccine. 2017;35(32):4085-4098. Doi:10.1016/j.vaccine.2017.03.098.
